Drug Target Review

MARCH 15, 2024

Emerging novel approaches to enable the workflow The development of biotherapeutic molecules has evolved significantly over the past two decades. Technology advancements have enabled a significantly more streamlined and efficient cell line development process. References Mistry RK, Kelsall E, Sou SN, et al.

Engineering 105

Engineering Molecular Biology Protein Expression Medical Schools 105

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues. Asia, and Europe.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

Drug Target Review

FEBRUARY 19, 2024

One of the teams I was humble to lead was the first to bring the development of cell lines for monoclonal antibody production to the critical path in the drug development workflow. Beate is an elected member of the Board of the Dechema, German Society for Chemical Engineering and Biotechnology. BECOME A ROLE MODEL!

Molecular Biology 110

Molecular Biology Science Protein Expression Production 110

Drug Target Review

SEPTEMBER 10, 2024

The current landscape of protein drug development is characterised by accelerated timelines where new drugs are approved in months rather than years. Hence, in many cases an earlier IND may be prevented by the timely provision of representative Drug Substance (DS) to execute such toxicology studies.

Drug Development 64

Drug Development Clinical Supply Production FDA 64

The Pharma Data

DECEMBER 8, 2020

AbCellera’s AI-powered antibody discovery platform speeds the otherwise lengthy and grueling process by analyzing the database of natural immune systems to find antibodies that can be developed into drugs. Tackle the toughest problems in drug development.” The promise to partners is to “move quickly. Reduce cost.

RNA 52

RNA Therapies Disease Protein Expression 52

The Pharma Data

OCTOBER 26, 2020

Christophe Le Tourneau, MD, Head of the Department of Drug Development and Innovation (D3i) at the Curie Institute, and Principal Investigator of the trial , added: “We have seen very encouraging efficacy results in this hard-to-treat patient population, as well as a satisfying safety profile. Christophe Le Tourneau, M.D.,

Vaccine 40

Vaccine Trials Treatment Virus 40